Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients

Annals of Oncology

Volumn 9, Issue 2, 1998, Pages 221-223

  Staib, P ^a   Lathan, B ^a   Knoppel Schwark S ^a   Tesch, H ^a   Voliotis, D ^a   Steinmetz, H T ^a   Schwonzen, M ^a   Wickramanayake, P D ^a   Diehl, V ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Aclarubicin; Acute myeloid leukemia; Cytosine arabinoside; Elderly; Etoposide

Indexed keywords

ACLARUBICIN; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HYPOPLASIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SURVIVAL TIME;

EID: 0031935741     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008235801218     Document Type: Article

References (12)

1. Walters RS, Kantarjian HM, Keating MJ et al. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 1987; 60: 149-5.
2. Büchner T, Hiddemann W, Wörmann B et al. Chemotherapy intensity and long-term outcome in AML. In Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J (eds): Acute Leukemias IV. Berlin/Heidelberg: Springer-Verlag 1994; 513-8.
3. Wiernik PH, Banks PL, Case DC Jr et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-9.
4. Tone H, Nishida H, Takeuchi T, Umezawa H. Experimental studies on aclacinomycin. Drugs Exp Clin Res 1985; 9-15.
5. Hansen OP, Pedersen-Bjergaard J, Ellegaard J et al Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: A danish national phase III trial. Leukemia 1991; 5: 510-6.
6. Dong J, Naito M, Tatsuta T et al. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol Res 1995; 7: 245-52.
7. Mailliard JA, Letendre L, Dalton RJ, et al. Phase I-II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia. Med Pediatr Oncol 1986; 14: 306-9.
8. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896-903.
9. Heyll A, Aul C, Gogolin F, et al. Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia. Ann Hematol 1994; 68: 279-83.
10. Jehn U. Phase II-trial of double-consolidation following intensive induction treatment for improvement of survival in elderly patients with acute myeloid leukemia. Leuk Lymph 1994; 12: 435-40.
11. Taylor PR, Reid MM, Stark AN, Bown N, Hamilton PJ, Proctor SJ. De novo acute myeloid leukaemia in patients over 55-years-old: A population-based study of incidence, treatment and outcome. Leukemia 1995; 9: 231-7.
12. Johnson PR, Hunt LP, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: Development of a model to predict survival. Br J Haematol 1993; 85: 300-6.